The new AtriClip® FLEX-Mini™ Device offers surgeons the same one-handed deployment capability we know works well while excluding the left atrial appendage with a closed-ended deployment.​
​
Learn more: <a href="https://okt.to/akgrvc&quot; target="_blank">https://okt.to/akgrvc</a&gt;

AtriCure is proud to partner with the Cincinnati Museum Center’s STEM Girls outreach programs, where we recently engaged with the next generation of innovators, scientists, and leaders. As a top workplace for women innovators, we are dedicated to highlighting careers in the medical device industry and empowering these young talents to create bright futures.​

Congratulations to Dr. Bruce Cannon and the <a href="https://twitter.com/NormanRegional&quot; target="_blank">@NormanRegional</a> team on their first case with cryoSPHERE® MAX! ​
Discover how Cryo Nerve Block is swapping pain for numbness in cardiac and thoracic patients: <a href="https://t.co/OspTMNeH5K&quot; target="_blank">https://t.co/OspTMNeH5K</a&gt;
​
<a href="https://twitter.com/hashtag/PainManagement?src=hashtag_click&quot; target="_blank">#PainManagement</a> <a href="https://twitter.com/hashtag/cryoNB?src=hashtag_click&quot; target="_blank">#cryoNB</a>

Congratulations to Dr. Bruce Cannon and the Norman Regional Health System team on their first case with cryoSPHERE® MAX! ​

Discover how Cryo Nerve Block is swapping pain for numbness in cardiac and thoracic patients: <a href="https://okt.to/AVHOa2&quot; target="_blank">https://okt.to/AVHOa2</a&gt;
<a href='https://www.linkedin.com/feed/hashtag/?keywords=PainManagement&highligh…; target='_blank'>#PainManagement</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=cryoNB&highlightedUpdat…; target='_blank'>#cryoNB</a>

The CEASE-AF trial shows Hybrid ablation’s ~33% improvement in freedom from atrial arrhythmias* over 24 months for LSPAF**. Discover more about Hybrid AF™ Therapy at <a href="https://twitter.com/hashtag/AHA2024.?src=hashtag_click" target="_blank">#AHA2024.</a> Learn more here: <a href="https://t.co/Zs4xjdLb6U&quot; target="_blank">https://t.co/Zs4xjdLb6U</a&gt; ​

*Freedom from atrial arrhythmias (atrial fibrillation,… <a href="https://t.co/JWybCCHKUx&quot; target="_blank">https://t.co/JWybCCHKUx</a&gt;

The CEASE-AF trial highlights Hybrid ablation’s impressive long-term durability, showing a ~33% improvement in freedom from atrial arrhythmias* over 24 months for patients with long-standing persistent Afib**. Learn more about the compelling data behind Hybrid AF™ Therapy at <a href='https://www.linkedin.com/feed/hashtag/?keywords=AHA2024.&highlightedUpd…; target='_blank'>#AHA2024.</a>​
​
In the meantime, explore further here: <a href="https://okt.to/qy0uc3&quot; target="_blank">https://okt.to/qy0uc3</a&gt; ​
​
*Freedom from atrial arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia) off anti-arrhythmic drugs (AADs) except previously failed AADs at doses not exceeding those previously failed​​
**Persistent atrial fibrillation with enlarged left atrium and longstanding persistent Afib​​

At the China Minimally Invasive Cardiovascular Surgery Conference (CMC Week 2024), we were honored to have Dr. Eric Lehr share his expertise on the surgical treatment of Afib with cardiac surgeons in China. Restoring and maintaining normal sinus rhythm is essential for improving patient outcomes, and treating Afib effectively is a critical part of that goal. A big thank you to the physicians who visited with us and exchanged valuable insights on surgical Afib treatment, now a Class Ia recommendation.

Q3 financial results are in. With unwavering dedication to advancing Afib treatment options and enhancing post-operative patient care, we have continued to expand our product portfolio and global reach. Read the earnings report at:: <a href="https://t.co/aeBPb9Aar6&quot; target="_blank">https://t.co/aeBPb9Aar6</a&gt;
<a href="https://twitter.com/hashtag/earnings?src=hashtag_click&quot; target="_blank">#earnings</a>

Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business. <a href="https://twitter.com/hashtag/ThisIsAtriCure?src=hashtag_click&quot; target="_blank">#ThisIsAtriCure</a>

Q3 financial results are in. With unwavering dedication to advancing Afib treatment options and enhancing post-operative patient care, we have continued to expand our product portfolio and global reach.

Discover the impact of our progress in the full earnings report here: <a href="https://okt.to/OdenYD&quot; target="_blank">https://okt.to/OdenYD</a&gt;
<a href='https://www.linkedin.com/feed/hashtag/?keywords=earnings&highlightedUpd…; target='_blank'>#earnings</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=FinancialResults&highli…; target='_blank'>#FinancialResults</a>